

AMENDMENTS TO THE CLAIMS:

Claims 1-5, 9, 10, 11, and 14 contain proposed amendments according to the reissue amendment format governed by 37 CFR 1.173. i.e., using appropriate markings in respect to the text of the original patent. Moreover, according to 37 CFR 1.173 (b)(2), only those claims being amended in the instant amendment are presented. Claims 1-15 are pending in the referenced reissue application. The proposed amendments should replace all prior versions and listings of claims in the reissue application. Please enter these claims as amended.

Listing of Claims:

1. (Currently amended) A peptide [that comprises] consisting of at least two contiguous LHRH decapeptide sequences wherein the amino acid glycine at position 6 of at least one of the constituting LHRH decapeptides is replaced by a dextrorotatory amino acid with a side chain that can be coupled to a carrier compound wherein said contiguous LHRH decapeptide sequences are joined with a terminus to terminus linkage.

2. (Currently amended) A peptide [according to claim 1] characterised in that it comprises an amino acid sequence that comprises the structure (SEQ ID NO: 4):


1 6 16 21
#EHWSY*LRPGQHWSY*LRPGC

wherein the amino acid * at position 6 or 16 is a dextrorotatory amino acid with a side chain that can be coupled to a carrier compound and the other amino acid * is either glycine or a dextrorotatory amino acid with a side chain that can be coupled to a carrier compound wherein said contiguous LHRH decapeptide sequences are joined with a terminus to terminus linkage.

3. (Currently Amended) [Peptides according to claim 1 that] A peptide that comprises at least two contiguous LHRH decapeptide sequences wherein the amino acid glycine at position 6 of at least one of the constituting LHRH decapeptides is replaced by a dextrorotatory amino acid with a side chain that can be coupled to a carrier compound wherein said decapeptides are joined


with an N-terminus to N-terminus linkage, or C-terminus to C-terminus linkage and are dimerised or multimerised.

4. (Currently amended) A peptide according to claim 3 and comprising the structure:



wherein the amino acid * at position 6 or 16 or 27 or 37 is D-lysine or D-glutamine or another dextrorotatory amino acid with a side chain that can be coupled to a carrier compound and the other amino acid * is either glycine or D-lysine or D-glutamine or another dextrorotatory amino acid with a side chain that can be coupled to a carrier compound.

5. (Currently Amended) A peptide [according to claim 3 and] having the structure (SEQ ID NO: 7 where residue 22 is Cys):



wherein the pyroglutamic acid residue at position 1 of LHRH is replaced with a glutamine and a cysteine is placed before the glutamine at position 1 in LHRH and the amino acid * at position [6 or 16 or 27 or 37] 7 or 17 or 29 or 39 is D-lysine or D-glutamine or another dextrorotatory amino acid with a side chain that can be coupled to a carrier compound and the other amino acid * is either glycine or D-lysine or D-glutamine or another dextrorotatory amino acid with a side chain that can be coupled to a carrier compound.

9. (Currently amended) A [composition] peptide in accordance with [claims] claim 1 [additionally comprising] combined with a mild adjuvant.

Reply Under 37 CFR 1.116 --- Expedited Procedure --- Technology Center 1600
Serial No.: 09/876,257

10. (Currently amended) A [composition] peptide in accordance with claim 9 wherein the mild adjuvant is an oil phase of a water-in-oil emulsion or a double oil emulsion.

11. (Currently amended) A vaccine comprising a [composition] peptide in accordance to claim 1.

14. (Currently Amended) A method to [effect] affect one or more reproductive or behavioral characteristics of an animal, characterized in that said animal is vaccinated in accordance with claim 12.

Reply Under 37 CFR 1.116 --- Expedited Procedure --- Technology Center 1600
Serial No.: 09/876,257

STATUS OF CLAIMS

Claims 1-15 are pending in this reissue application.